Healthcare
Chugai Pharmaceutical Co., Ltd.(CHGCF)
Live Price
Offline$45.93
-1.46% today
1Y Change
-15.65%
Window
Jun 26, 2025 โ Jun 18, 2026
- Market Cap
- $13.57T
- Revenue Growth
- +7.6%
- EPS Growth
- +12.2%
- Dividend Yield
- 3.3%
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Chugai Pharmaceutical Co., Ltd. (CHGCF) is a Healthcare stock with a market cap of $13.57T and listed on OTC. The stock last traded around $45.93 and down 15.6% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +7.6%, EPS growth of +12.2%, a dividend yield of 3.3%. What stands out right now is revenue +7.6%, EPS +12.2%, free cash flow -20.2% with operating margin 47.6% and ROIC 23.0%. The dividend matters to the case here, with a current yield around 3.3%. Valuation already assumes a fairly strong business story at P/E 30.0 and price/sales 10.5. Stock Foundry combines CHGCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.6% vs +7.6% peer median
Operating Margin
Above sector median
+47.6% vs +19.4% peer median
P/E
Below sector median
30.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 24, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +7.6% and EPS at +12.2%, with operating margin around 47.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 24, 2026 | โ | -15.3% | -2.8% | -4.4% |
2026 Jan 29, 2026 | +5.5% | +4.8% | +0.3% | +22.3% |
2025 Jul 24, 2025 | -20.7% | +0.4% | +8.5% | -10.1% |
Benchmark Edge
CHGCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHGCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHGCF Max Drawdown
-33.78%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHGCF and SPY.
Company Overview
Chugai Pharmaceutical Co., Ltd.
OTC
Chugai Pharmaceutical Co., Ltd. is a leading research-based pharmaceutical company in Japan, known for its innovative approach to drug development. The primary function of Chugai Pharmaceutical is to discover, develop, and distribute new medications that address unmet medical needs across various therapeutic areas. The company places a significant emphasis on oncology, immunology, and hematology, leveraging advanced biotechnology to create biopharmaceutical solutions. A member of the Roche Group, Chugai Pharmaceutical benefits from a strong global network, enhancing its research capabilities and market reach. The company is instrumental in advancing healthcare standards, providing cutting-edge therapies, and improving patient outcomes. Through strategic collaborations and a firm commitment to R&D, Chugai Pharmaceutical continues to hold a significant role in the global pharmaceutical market, symbolizing innovation and quality in the healthcare industry.
- Leadership
- Dr. Osamu Okuda
- Employees
- 5.1k
- Street Address
- Nihonbashi Mitsui Tower, Reception12F 1-1 Nihonbashi-Muromachi 2-chome
- Mailing
- Chuo, 103-8324
- Region
- Chuo, Japan
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 30.0
- EV/EBITDA
- 19.8
- Price/Sales
- 10.5
- Price/Book
- 7.1
Growth
- Revenue
- +7.6%
- EPS
- +12.2%
- Free Cash Flow
- -20.2%
Profitability
- Gross Margin
- 71.4%
- Operating Margin
- 47.6%
- Net Margin
- 35.0%
- ROE
- 23.2%
- ROIC
- 23.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 4.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.